Tuberculosis and chronic respiratory disease: A systematic review

International Journal of Infectious Diseases

Volumn 32, Issue , 2015, Pages 138-146

  Byrne, Anthony L ^a,b,c   Marais, Ben J ^a,c,d   Mitnick, Carole D ^b,e   Lecca, Leonid ^b   Marks, Guy B ^a,c,f  

^a UNIVERSITY OF SYDNEY   (Australia)

^b PARTNERS IN HEALTH   (United States)

^c Centre for Research Excellence in Tuberculosis (TB CRE)   (Australia)

^d University of Sydney   (Australia)

^e HARVARD MEDICAL SCHOOL   (United States)

^f WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Bronchiectasis; Chronic Obstructive Pulmonary Disease; Chronic Respiratory Disease; Systematic Review; Tuberculosis

Indexed keywords

AGE; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL FEATURE; COCHRANE LIBRARY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; HUMAN; INCIDENCE; META ANALYSIS (TOPIC); NATIONAL HEALTH ORGANIZATION; QUALITY CONTROL; RESPIRATORY FUNCTION; REVIEW; RISK FACTOR; SMOKING; SYSTEMATIC REVIEW; TUBERCULOSIS; ADULT; CHRONIC DISEASE; COMPLICATION; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADULT; BRONCHIECTASIS; CHRONIC DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84925233244     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.12.016     Document Type: Review

References (72)

1. Marais B., Lönnroth K., Lawn S., et al. Tuberculosis co-morbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis 2013, 13:436-448.
2. Bygbjerg I.C. Double burden of noncommunicable and infectious diseases in developing countries. Science 2012, 337:1499-1501.
3. Bouquet J., Dahl R., Khaltaev N. Global alliance against chronic respiratory diseases. Eur Respir J 2007, 29:233-239.
4. World Health Organisation Global Tuberculosis Report 2014. Available online at; (Accessed 2nd November 2014). http://www.who.int/tb/publications/global_report/en/.
5. Zumla A., Raviglione M., Hafner R., Fordham von Reyn C. Tuberculosis N Engl J Med 2013, 368:745-755.
6. Huang C.C., Tchetgen E.T., Becerra M.C., Cohen T., Galea J., Calderon R., et al. Cigarette smoking among tuberculosis patients increases risk of transmission to child contacts. Int J Tuberc Lung Dis. 2014 Nov, 18(11):1285-1291.
7. Scarselli A., Binazzi A., Forastiere F., Cavariani F., et al. Industry and job-specific mortality after occupational exposure to silica dust. Occupational Med 2011, 61:422-429.
8. Leung C.C., Yew W.W., Law W.S., Tam C.M., Leung M. Smoking and tuberculosis among silicotic patients. Eur Resp J 2007, 29:745-750.
9. Jeon C.Y., Murray M.B. Diabetes Mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008, 5:1091-1101. 10.1371/journal.pmed.0050152.
10. Whiting D.R., Guariguata L., Weil C., Shaw J. IDF Diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Prac 2011, 94(3):311-321.
11. Van Zyl Smit R.N., Pai M., Yew W.W., Leung C.C., et al. Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur Resp J 2010, 35:27-33.
12. Hnizdo E., Singh T., Churchyard D. Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax 2000, 55:32-38.
13. Lopez A.D., Mathews C.D., Ezzati M., Jamison D.T., Murray C.J.L. Global burden of disease and risk factors 2006, The World Bank, Washington.
14. Buist S., Vollmer W.M., McBurnie M.A. Worldwide burden of COPD in high- and low-income countries. Part I. The burden of obstructive lung disease (BOLD) initiative. Int J Tuberc Lung Dis 2008, 12:703-708.
15. Abegunde D.O., Mathers C.D., Adam T., Ortegon M., et al. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007, 370:1929-1938.
16. Jiang Y., Elton-Marshall T., Fong G.T., Li Q. Quitting smoking in China: findings from the ITC China survey. Tobacco Control 2010, 19:12-15.
17. Gan Q., Smith K.R., Hammond S.K., et al. Disease burden of adult lung cancer and ischaemic heart disease from passive tobacco smoking in China. Tob Control 2007, 16:417-422.
18. Lienhardt C. From exposure to disease: the role of environmental factors in susceptibility to and development of tuberculosis. Epidemiol Rev 2001, 23(2):288-301.
19. Murray C.J., Lopez A.D. Measuring the global burden of disease. N Engl J Med 2013, 369:448-457.
20. World Health Organisation website. Available online at; (Accessed 3rd November, 2014). http://www.who.int/respiratory/en/.
21. Lozano R., Naghavi M., Foreman K., Lim S., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
22. Roberts H., Wells A., Milne D., Rubens M., et al. Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. Thorax 2000, 55(3):198-204.
23. Morrissey B.M., Evans S.J. Severe Bronchiectasis. Clin Rev Allergy Imm 2003, 25:233-247.
24. Rosen M.J. Chronic cough due to bronchiectasis. Chest 2006, 129:122s-131s.
25. Martinez-Garcia M.A., Soler-Cataluna J.J., Perpina-Tordera M., Roman-Sanchez P. Factors associated with lung function decline in adult patients with stable non-cystic bronchiectasis. Chest 2007, 132:1565-1572.
26. Martinez-Garcia M.A., Perpina-Tordera M., Roman-Sanchez P., Soler-Cataluna J.J. Quality of life determinants in patients with clinically stable bronchiectasis. Chest 2005, 128:739-745.
27. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. BMJ 2009, 339:B2535.
28. United States Library of Medicine website. Introduction to medical subject headings. Available online at; (Accessed November 17th, 2014). http://www.nlm.nih.gov/mesh/introduction.html.
29. National Heart Lung and Blood Institute website. Development and Use of Quality Assessment Tools. Available online at; (Accessed on November 2, 2014). http://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/background.htm.
30. DerSimonian R., Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials. 1986, 7:177-188.
31. Senn S., Weir J., Hua T.A., Berlin C., Branson M., Glimm E. Creating a suite of macros for meta-analysis in SAS®: A case study in collaboration. Statistics & Probability Letters. 2011, 81:842-851.
32. Higgins J.P.T., Thompson S.G. Quantifying heterogeneity in meta-analysis. Stat Med 2002, 21:1539-1558.
33. Hooper R., Burney P., Vollmer W.M., McBurnie M., et al. Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project. Eur Resp J 2012, 39:1343-1353.
34. Lee S.W., Kim Y.S., Kim D.S., Oh Y.M., et al. The risk of obstructive lung disease by previous pulmonary tuberculosis in a country with intermediate burden of tuberculosis. J Korean Med Sc 2011, 26:268-273.
35. Idolor L.F., De Guia T., Fransisco N.A., Roa C.C., et al. Burden of obstructive lung disease in a rural setting in the Philippines. Respirology 2011, 16:1111-1118.
36. Menezes A.M.B., Hallal P.C., Perez-Padilla R., Jardim J.R., et al. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur Resp J 2007, 30:1180-1185.
37. Caballero A., Torres-Duque C.A., Jaramillo C., Bolivar F., et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest 2008, 133:343-349.
38. Lee C.H., Lee M.C., Lin H.H., Shu C.C., et al. Pulmonary tuberculosis and delay in anti-tuberculous treatment are important risk factors for chronic obstructive pulmonary disease. Plos one 2012, 7.
39. Ehrlich R.I., Norman R., Laubscher R., et al. Predictors of chronic bronchitis in adults in South Africa. Int J Tuberc Lung Dis 2004, 8:369-376.
40. Perez-Padilla R., Fernandez R., Lopez Varela M., Montes de Oca M., et al. Airflow obstruction in never smokers in five Latin American cities: the PLATINO study. Arch. Med Res 2012, 43:159-165.
41. Lamprecht B., McBurnie M.A., Vollmer W., Gudmundosson G., et al. COPD in Never Smokers Results From the Population-Based Burden of Obstructive Lung Disease Study. Chest 2011, 4:752-763.
42. Zhou Y.M., Wang C., Yao W.Z., Chen P., et al. The prevalence and risk factors of bronchiectasis in residents aged 40 years old and above in seven cities in China. Chinese J Int Med 2013, 52:379-382.
43. Kwak H.J., Moon J.Y., Choi Y.W., Kim T.H., et al. High prevalence of bronchiectasis in adults: analysis of CT findings in a health screening program. Tohoku J Exp Med 2010, 222:237-242.
44. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: Revised 2014. Global Initiative for Chronic Obstructive Lung Disease (GOLD). (Accessed on October 31, 2014). http://www.goldcopd.org/.
45. Clark K.D., Wardrobe-Wong N., Elliott J.J., Gill P.T., et al. Cigarette smoke inhalation and lung damage in smoking volunteers. Eur Respir J 1998, 12:395-399.
46. Lokke A., Lange P., Scharling H., Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax 2006, 61:935-939.
47. Salvi S.S., Barnes P.J. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009, 374:733-743.
48. Buist S., Vollmer W.M., Sullivan S.D., Weiss K.B., et al. The burden of obstructive lung disease initiative (BOLD): rationale and design. Journal of COPD 2005, 2:277-283.
49. Menezes A.M.B., Victoria C.G., Perez-Padilla R. The Platino Project: methodology of a multicentre prevalence survey of chronic obstructive pulmonary disease in major Latin American cities. BMC Med Res 2004, 4:15.
50. Akkara S.A., Shah A.D., Adalja M., Akkara A.G., et al. Pulmonary tuberculosis: the day after. Int J Tuberc Lung Dis 2013, 17:810-813.
51. Rhee C.K., Yoo K.H., Lee J.H., Park M.J., et al. Clinical characteristics of patients with tuberculosis-destroyed lung. Int J Tuberc Lung Dis 2013, 17:67-75.
52. Baig IM, Saeed W, Khalil KF. Post-tuberculous chronic obstructive pulmonary disease. JCPSP;20:542-4.
53. Tsuboi T., Chin K., Machida K., Ohi M. [Noninvasive positive pressure ventilation in patients with acute exacerbations of pulmonary tuberculosis sequelae]. J Jap Res Soc. 2006, 44:160-167.
54. Burney P., Jithoo A., Kato B., et al. Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty-a BOLD analysis. Thorax 2014, 69:465-473.
55. Apostu M., Mihaescu T. (Ventilatory defects in patients with pulmonary tuberculosis). Pneumologia 2013, 62:148-157.
56. Cruz R.S., De Albuquerque M.F., Costa e Silva E., Mazza E., et al. [Pulmonary tuberculosis: association between extent of the residual pulmonary lesion and alteration in the lung function]. Revista da Associcao Medica Brasileira 1992, 54:406-410.
57. De Valliere S., Barker R.D. Residual lung damage after completion of treatment for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2004, 8:767-771.
58. Plit M.L., Anderson R., Van Rensberg C.E.J., Page-Shipp L., et al. Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur Respir J. 1998, 12:351-356.
59. Barker A.F. Bronchiectasis. N Engl J Med 2002, 346:1383-1393.
60. Crae T. Osler's Principles and Practice of Medicine 1926, 628. D. Appleton and Co, New York. 10th ed.
61. Grancher J.J. La dilatation des bronches chez les tuberculeux,. Gazz.Med.de Paris April 1878, No.146.
62. Salkin D. Tuberculosis as a cause of upper lobe bronchiectasis. Cal Med. 1950, 73:577-580.
63. Hansell D.M. Bronchiectasis. Radiol Clin North Am 1998, 36:107-128.
64. Lee E.S., Park C.M., Goo J.M., Yim J.J., et al. Computed tomography features of extensively drug-resistant pulmonary tuberculosis in non-HIV-infected patients. J of Comp Asis Tom. 2010, 34:559-563.
65. Yeom J.A., Jeong Y.J., Jeon D., Kim K., et al. Imaging findings of primary multidrug-resistant tuberculosis: a comparison with findings of drug-sensitive tuberculosis. J of Comp Asis Tom 2009, 33:956-960.
66. Bhatta N., Dhakal S.S., Rizal S., Kralingen K.K., et al. Clinical spectrum of patients presenting with bronchiectasis in Nepal: evidence of linkage between tuberculosis, tobacco smoking and toxic exposure to biomass smoke. KUMJ; 2008, 6:195-203.
67. Lee C.H., Kim K., Hyun M.K., Jang E.J., et al. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax 2013, 68:1105-1113.
68. Kim J.H., Park J.S., Kim K.H., Jeong H.C., et al. Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. Chest 2013, 143:1018-1024.
69. Brassard P., Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J CC Med 2011, 183:675-678.
70. Shu C.C., Wu H.D., Yu M.C., Wang J.T. Use of high-dose inhaled corticosteroids is associated with pulmonary tuberculosis in patients with chronic obstructive pulmonary disease. Medicine 2010, 89:53-61.
71. Maninno D.M., Buist S.B. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007, 370:765-773.
72. The World Bank website. Available online at; (Accessed on November 3, 2014). http://www.worldbank.org/depweb/english/modules/social/pgr/chart1a.html.